During the last session, Bluebird bio Inc (NASDAQ:BLUE)’s traded shares were 8.18 million, with the beta value of the company hitting 0.82. At the end of the trading day, the stock’s price was $0.92, reflecting an intraday loss of -4.91% or -$0.05. The 52-week high for the BLUE share is $5.53, that puts it down -501.09 from that peak though still a striking 4.35% gain since the share price plummeted to a 52-week low of $0.88. The company’s market capitalization is $177.88M, and the average trade volume was 8.39 million shares over the past three months.
Bluebird bio Inc (NASDAQ:BLUE) trade information
Bluebird bio Inc (BLUE) registered a -4.91% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.91% in intraday trading to $0.92, hitting a weekly high. The stock’s 5-day price performance is -4.19%, and it has moved by -32.14% in 30 days. Based on these gigs, the overall price performance for the year is -73.17%.
Bluebird bio Inc (BLUE) estimates and forecasts
In the rating firms’ projections, revenue will increase 881.40% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 10.16M as predicted by 11 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to 19.55M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 62k and 2.38M respectively. In this case, analysts expect current quarter sales to grow by 16,287.10% and then jump by 721.10% in the coming quarter.
While earnings are projected to return 10.88% in 2024, the next five years will return 45.80% per annum.
BLUE Dividends
Bluebird bio Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
